For example, Zolgensma, a gene therapy approved for spinal muscular atrophy (SMA), delivers a functional copy of the SMN1 gene via an adeno-associated virus (AAV) vector, restoring the production of survival motor neuron protein. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.